Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 1/20 | 0.57 |
| ▸ | ADK | P55263 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11071618 | 1.00 | ADA (0.57) | ADAADKLMNATHRBMTOR | |
| SCHEMBL10335631 | 1.00 | ADA (0.57) | ADAADKLMNATHRBMTOR | |
| SCHEMBL11081361 | 1.00 | ADA (0.57) | ADAADKLMNATHRBMTOR | |
| SCHEMBL6731302 | 0.86 | MEN1 (0.48) | ADAADK | |
| SCHEMBL1739666 | 0.86 | MEN1 (0.48) | ADAADK | |
| SCHEMBL1738174 | 0.81 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6738327 | 0.81 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL29484023 | 0.81 | CA2 (0.47) | ADK | |
| SCHEMBL23982303 | 0.81 | MAPT (0.60) | ADKLMNATHRBMTORMDM2 | |
| SCHEMBL20419150 | 0.81 | MAPT (0.60) | ADKLMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133080-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2017-02-22 | — | — | EP | disclosed |
| WO-2010135520-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-7202223-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20060079468-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-4140851-A | Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079468-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADA 12/4885ADK 190/4885LMNA 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.